Immunicum AB (STO:IMMU), a biopharmaceutical company developing therapeutic cancer vaccines, reported on Thursday a change in the number of shares and votes in the company, as a result of the implementation of a share issue with preferential rights for the company's existing shareholders.
Under this rights issue, the number of shares and votes have increased by 20,383,412, which has increased the company's share capital by SEK 1,019,170.60.
As of 31 January 2019, the total share capital in Immunicum amounts to SEK4,612,876.55 and the total number of shares and votes amount to 92,257,531.
(EUR1.00=SEK10.36)
Centivax Inc doses first healthy volunteers in Centi-Flu 01 Phase 1A clinical trial
Delonix Bioworks gets IND clearance for DX-104 in China
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
European Commission approves GSK's Arexvy for adults aged 18 and over
GSK wins European Commission approval for Shingrix prefilled syringe
Sanofi agrees USD2.2bn acquisition of Dynavax to strengthen adult vaccine portfolio
ECO Animal Health Group secures EU approval for ECOVAXXIN MS
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic